Epithelial Ovarian Cancer Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025
- Transparency Market Research
Epithelial ovarian cancer is a disease in which malignant cells develop in the tissue that covers the ovary. Epithelial ovarian cancer is common in women who have a close relation such as mother, daughter, or sister diagnosed with the disease. In case of women having two or more blood relatives with ovarian cancer, the risk of developing the disease is higher. The hereditary information is carried from one generation to another through carrier genes received from parents. It has been estimated that hereditary ovarian cancer is approximately 5% - 10% more prevalent when compared to other cases of ovarian cancer.
Symptoms of epithelial ovarian cancer include pain in the pelvis area, swelling in the abdomen, and gastrointestinal problems such as bloating, etc. Diagnosis of epithelial ovarian cancer is conducted through a series of procedures such as pelvic examination, ultrasound, CA 125 assay, barium enema, intravenous pyelogram (IVP), CT scan, and biopsy.
Epithelial ovarian cancer starts from the surface layer of the ovary. It has been estimated by the Cancer Research UK that 90% of the diagnosed ovary cancers are of this type. The epithelial ovarian cancer market can be classified on the basis of types of epithelial ovarian cancer, diagnostic techniques, and treatment methods. On the basis of type, the epithelial ovarian cancer market can be segmented into five categories: stage I, stage II, stage III, and stage IV. According to the Cancer Research UK, serous epithelial ovarian cancer accounts for two-third of the epithelial ovarian cancer diagnosed every year, while 10% of the epithelial ovarian cancer diagnosed are of undifferentiated type. Different types of treatments are available for patients suffering from epithelial ovarian cancer such as surgery, radiation therapy, chemotherapy, immunotherapy, and targeted therapy.
In surgery, the uterus, cervix, fallopian tubes, ovaries, and omentum are removed from the body which may include. Post-surgery, patients are treated with radiation therapy and chemotherapy in order to kill the remaining tumor cells. Primary drugs used for the chemotherapy of epithelial ovarian cancer patients include BEP, carboplatin-taxon, gemcitabine-cisplatin, and VeIP. In addition to these, two other therapies for the treatment of epithelial ovarian cancer are under clinical trials such as biologic therapy and targeted therapy. Biologic therapy uses the patient’s immune system to fight against cancer, while targeted therapy involves the usage of drugs that identify and kill cancer-affected cells without causing any harm to the normal cells. Bevacizumab and PARP inhibitors are two such drugs under clinical trials for targeted therapy. Other major drugs under clinical trials include trebananib, paclitaxel, CVac, cositecan, and trabectadin.
According to the National Cancer Institute, in U.S., 22,240 new cases were diagnosed with ovarian cancer and the disease was responsible for 14,030 deaths. Such high rate of incidence and mortality is driving the epithelial ovarian cancer market. Asia Pacific represents the highest opportunity for epithelial ovarian cancer market owing to the increase in number of epithelial ovarian cancer and rise in awareness about the disease. Statistics released by the Cancer Australia revealed that in 2010, there were 1,305 new cases of ovarian cancer in Australia and around 1,470 and 1,640 new cases of ovarian cancer were predicted to be diagnosed in 2014 and 2020, respectively.
Increase in incidences of ovarian cancer, rise in research and development in drugs, favorable reimbursement provisions in developed and developing economies, development in healthcare infrastructure, and surge in government initiatives to promote research and awareness about the disease are projected to drive the epithelial ovarian cancer market during the forecast period. However, the high cost of treatment, stringent regulation in drug testing, and lack of skilled professionals for early diagnosis of disease are anticipated to hinder the growth of the market.
The global epithelial ovarian cancer market can be divided into five geographical region: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America leads the epithelial ovarian cancer market, followed by Europe, due to high prevalence of the disease and extensive research and development activities. Increase in incidences of ovarian cancer is expected to drive the global epithelial ovarian cancer market in Asia Pacific during the forecast period. Latin America and Middle East & Africa region are also anticipated to provide lucrative opportunities to the epithelial ovarian cancer market in the next few years. It can be largely ascribed to the growing biopharmaceutical industry in the region and the rise in participation of private players for expanding their geographical presence.
Major players in the epithelial ovarian cancer market include Boehringer Ingelheim GmbH, Millennium Pharmaceuticals, Inc., Amgen, Inc., ImmunoGen, Inc., Pharmacyclics, Inc., Bayer AG, Synta Pharmaceuticals Corp., Prima BioMed, Ltd., Oasmia Pharmaceutical AB, and Glycotope GmbH.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
The study is a source of reliable data on:
- Market segments and sub-segments
- Market trends and dynamics
- Supply and demand
- Market size
- Current trends/opportunities/challenges
- Competitive landscape
- Technological breakthroughs
- Value chain and stakeholder analysis
The regional analysis covers:
- North America (U.S. and Canada)
- Latin America (Mexico, Brazil, Peru, Chile, and others)
- Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
- Eastern Europe (Poland and Russia)
- Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
- Middle East and Africa (GCC, Southern Africa, and North Africa)
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.
A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Highlights of the report:
- A complete backdrop analysis, which includes an assessment of the parent market
- Important changes in market dynamics
- Market segmentation up to the second or third level
- Historical, current, and projected size of the market from the standpoint of both value and volume
- Reporting and evaluation of recent industry developments
- Market shares and strategies of key players
- Emerging niche segments and regional markets
- An objective assessment of the trajectory of the market
- Recommendations to companies for strengthening their foothold in the market
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.
Have query on this report?Make an Enquiry
The team was the biggest help to us. Not only were we provided with customized solutions but also we were guided through the most complicated situations. The information was on-point yet comprehensive. The experience was absolutely satisfying and helped us turn many challenges into opportunities.
Ours is a startup with a unique set of challenges and we were therefore hesitant but the team totally put us at ease with their knowledge and expertise. Our business and its challenges were understood perfectly and help was extended accordingly. The tailor made approach really helped us gain the most informative insights.
The report repository is absolutely impressive –updated and exhaustive in terms of markets covered and information provides. Besides, with the support extended to us by the team, we could reduce costs as well as move to sustainable growth. This really helped us tap into new opportunities. Happy to have gone ahead with ResearchMos.us.
We have had a long term engagement with ResearchMoz.us and never have we felt that the work done and help extended were below flawless. The report repository is one of the best one can hope to tap into. Recently, our partner businesses opted for consultancy services and they are all thrilled with the outcome.
Insights from reports helped us improve our profit margins significantly. Most of the knowledge we needed on the market were provided to us on a granular basis. From trends, and drivers to competitive analysis, the information was not just crisp but also insightful. That helped us chart a robust growth strategy and as of now we are happy to state that we are reaping big benefits.
More from Pharmaceutical
PharmaceuticalChinese Markets for Mental Illness Drugs
PharmaceuticalChinese Markets for Anti-Dermatomycosis Skin Drugs
PharmaceuticalChinese Markets for Incretion Drugs
PharmaceuticalChinese Markets for Hypertension Drugs
Pharmaceuticals and HealthcareGlobal Bionic Ears Market Professional Survey Report 2017
Pharmaceuticals and HealthcareNeuropsychiatric Disorder Cluster Drug Development Pipeline Review, 2017
Pharmaceuticals and HealthcareHepatitis Drug Development Pipeline Review, 2017